Bioventus Inc.
BVS · XNASCIK 1665988fmd_1VMFVCSQDV6RNYJ47807AZ00Z0Manufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2019 to Sep 26, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 340 | 321 | 431 | 512 | 512 | 573 | 568 |
| Cost of revenue | 91 | 88 | 128 | 181 | 184 | 185 | 180 |
| Gross profit | 249 | 234 | 303 | 331 | 328 | 388 | 388 |
| Research and development | 11 | 11 | 19 | 24 | 13 | 14 | 12 |
| Selling, general and administrative | 198 | 193 | 254 | 332 | 304 | 344 | 314 |
| Operating income | 31 | 21 | 12 | (167) | (82) | (15) | 54 |
| Other non-operating income (expense) | (22) | (5) | (3) | (22) | (39) | (37) | (28) |
| Income before taxes | 10 | 16 | 9 | (189) | (121) | (52) | 26 |
| Income tax expense | 2 | 1 | (2) | (44) | 0 | (5) | (2) |
| Net income from continuing operations | 8 | 15 | 11 | (145) | (121) | (47) | 27 |
| Net income | 7 | 16 | 19 | (159) | (156) | (36) | 23 |
| Net income to common shareholders | – | – | – | (159) | – | – | – |